ORKAOruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions. Its current pipeline centers on treatments designed to target key pathways involved in immune-mediated skin and joint diseases, including plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The company’s lead programs include ORKA-001, which targets the interleukin-23 p19 subunit, and ORKA-002, which targets interleukin-17A and interleukin-17F. Oruka Therapeutics is also advancing additional programs and combination regimens intended to broaden its dermatology and immunology portfolio. Headquartered in Menlo Park, California, Oruka Therapeutics plays a role in the biotech sector by developing targeted biologic medicines for chronic inflammatory diseases.